NASDAQ:FLGTFulgent Genetics Stock Price, Forecast & News

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FLGT shares have increased by 73.2% and is now trading at $17.42. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fulgent Genetics.

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Fulgent Genetics.

Fulgent Genetics Inc (NASDAQ:FLGT) announced its quarterly earnings data on Monday, May, 4th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.05. The business earned $7.75 million during the quarter, compared to analysts' expectations of $7.69 million. Fulgent Genetics had a negative net margin of 1.31% and a positive return on equity of 0.52%. View Fulgent Genetics' earnings history.

5 Wall Street analysts have issued 12-month target prices for Fulgent Genetics' stock. Their forecasts range from $11.00 to $20.00. On average, they anticipate Fulgent Genetics' stock price to reach $14.46 in the next year. This suggests that the stock has a possible downside of 17.0%. View analysts' price targets for Fulgent Genetics.

Media coverage about FLGT stock has been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fulgent Genetics earned a news impact score of -1.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutFulgent Genetics.

Fulgent Genetics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 768,900 shares, an increase of 30.1% from the April 30th total of 590,800 shares. Based on an average trading volume of 401,200 shares, the short-interest ratio is presently 1.9 days. Currently, 8.1% of the company's shares are short sold. View Fulgent Genetics' Current Options Chain.

Some companies that are related to Fulgent Genetics include CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Biocept (BIOC), Miragen Therapeutics (MGEN), Psychemedics (PMD), OpGen (OPGN) and PotNetwork (POTN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Inseego (INSG), InVitae (NVTA), Marvell Technology Group (MRVL), NeoGenomics (NEO), Alibaba Group (BABA), Baidu (BIDU), Editas Medicine (EDIT) and Bilibili (BILI).

(FLGT) raised $60 million in an initial public offering (IPO) on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray served as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics' stock is owned by many different institutional and retail investors. Top institutional investors include Driehaus Capital Management LLC (3.08%), Raymond James Trust N.A. (1.56%), Ranger Investment Management L.P. (1.51%), Hillsdale Investment Management Inc. (1.47%), Russell Investments Group Ltd. (1.32%) and Acadian Asset Management LLC (1.01%). Company insiders that own Fulgent Genetics stock include John C Bolger, Ming Hsieh and Paul Kim. View institutional ownership trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Raymond James Trust N.A., Hillsdale Investment Management Inc., Essex Investment Management Co. LLC, Wedge Capital Management L L P NC, Alambic Investment Management L.P., EAM Investors LLC, Cornercap Investment Counsel Inc., and ClariVest Asset Management LLC. Company insiders that have sold Fulgent Genetics company stock in the last year include John C Bolger, and Paul Kim. View insider buying and selling activity for Fulgent Genetics.

FLGT stock was bought by a variety of institutional investors in the last quarter, including Ranger Investment Management L.P., Russell Investments Group Ltd., Parametric Portfolio Associates LLC, Driehaus Capital Management LLC, Acadian Asset Management LLC, Bank of New York Mellon Corp, Morgan Stanley, and New York State Common Retirement Fund. View insider buying and selling activity for Fulgent Genetics.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FLGT stock can currently be purchased for approximately $17.42.

Fulgent Genetics has a market capitalization of $378.01 million and generates $32.53 million in revenue each year. The company earns $-410,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Fulgent Genetics employs 123 workers across the globe.

The official website for Fulgent Genetics is www.fulgentgenetics.com.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE SUITE 205, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]